学术报告

您所在的位置:首页 >> 学术科研 >> 学术报告 >> 正文

药学前沿大讲堂329讲

点击数:529 作者:药学院 编辑:药学院 来源:药学院 提醒时间:2017-09-09

题目:The pharmacogenomics of asparaginase immune responses:  preventing and overcoming immunotoxicity.

报告人:Christian A. Fernandez,美国匹兹堡大学,教授

主持人:徐峻 中山大学药学院,教授

时间:201799日(周六)上午9:30

地点:中山大学广州校区东校园药学院125报告厅

 

报告人简介:

    Dr. Fernandez earned his Ph.D. from the Department of Pharmaceutics at the University of Iowa, where his dissertation research concentrated on the development of PEGylated polyacridine peptides for in vivo gene delivery of plasmid DNA. In 2010, he joined the Department of Pharmaceutical Sciences at St. Jude Children’s Research Hospital under the mentorship of Mary Relling. His postdoctoral training was broad in context but uniformly directed towards improving the treatment of pediatric acute lymphoblastic leukemia. His projects included analyzing retrospective clinical trial data, performing genetic association analyses related to the adverse effects of medications used to treat leukemia, and creating murine models of adverse drug reactions. He joined the Center for Pharmacogenetics and the Department of Pharmaceutical Sciences at the University of Pittsburgh School of Pharmacy in 2015, where his current research interest include the adverse drug reactions to the chemotherapeutic agent, asparaginase, which is one of the essential agents used during the treatment of pediatric leukemias and lymphomas. Specifically, his research focuses on the immune response to asparaginase, which can decrease drug levels of asparaginase and lead to worse treatment outcome. His research aims are to identify patients that may be genetically predisposed to developing an immune response to the drug, to determine therapeutic strategies for preventing or managing the immune response, and to develop a clinical laboratory test that can identify asparaginase-sensitized patients prior to their next course of treatment.

 

分享本文: